Topical application of a cyclic GMP analog lowers IOP in normal and ocular hypertensive rabbits.

PURPOSE To determine whether a new cyclic GMP analog, 2'-O-(4-benzoyl)benzoylguanosine 3',5' cyclic monophosphate (BB-cGMP), significantly reduces intraocular pressure in either normotensive or hypertensive eyes of rabbits. METHODS Intraocular pressure of normal adult rabbits and/or rabbits with alpha-chymotrypsin-induced ocular hypertension was measured after topical application of BB-cGMP for up to 72 hours after treatment. RESULTS Data indicate that topical application of solutions containing BB-cGMP can significantly reduce intraocular pressure in normotensive eyes and, to a greater extent, hypertensive eyes for periods up to 12 hours for a single dose. CONCLUSIONS BB-cGMP holds interest both as a clinical agent in the management of intraocular pressure and for in vitro biochemical studies on the regulation of intraocular pressure.